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Background
Mitochondrial aldehyde dehydrogenase (ALDH2) plays
an essential role in nitroglycerin (GTN) bioactivation,
resulting in formation of nitric oxide (NO) or a related
activator of soluble guanylate cyclase (sGC) and conse-
quently in cGMP-mediated vasorelaxation [1]. ALDH2
denitrates GTN to 1,2-glyceryl dinitrate (1,2-GDN) and
nitrite but also catalyzes reduction of GTN to nitric oxide
(NO) [2]. To elucidate the mechanism of ALDH2-cata-
lyzed GTN bioactivation in relation to the established
ALDH2 activities (dehydrogenase, esterase), we compared
the function of the wildtype (WT) enzyme with a mutant
lacking the general base Glu268 (E268Q).
Results
Despite low dehydrogenase and esterase activities (<3% of
WT) the E268Q mutant exhibited virtually unaffected
rates of GTN denitration (133 ± 11% of WT). The nucle-
otide cofactor NAD caused a pronounced increase in the
rates of 1,2-GDN formation by WT-ALDH2 from 1.21 ±
0.18 to 8.73 ± 0.09 nmol × min-1 × mg-1, but inhibited the
reaction catalyzed by the E268Q mutant to about 3% of
WT. In contrast to WT-ALDH2, the E268Q mutant gener-
ated detectable NO measured with a Clark-type electrode
even in the absence of superoxide dismutase (SOD). The
apparent initial rate was 2.1 ± 0.31 nmol × min-1 × mg-1
and the peak concentration of NO was 0.17 ± 0.03 μM.
Purified sGC was activated by GTN in the presence of
increasing amounts of WT-ALDH2, but the effect reached
a plateau of about 30% of maximal sGC activity at 50–100
μg of ALDH2 (9.0 ± 0.38 μmol cGMP × min-1 × mg-1).
Superoxide dismutase markedly potentiated the effect of
ALDH2, resulting in maximal sGC activation with 25 μg
of protein. With E268Q-ALDH2, maximal sGC activation
was observed with 100 μg of protein even in the absence
of SOD. In the presence of SOD, the effect of the mutant
was virtually identical to that of WT-ALDH2. Formation of
superoxide was confirmed by determination of hydroethi-
dine oxidation that was inhibited by SOD and the ALDH2
inhibitor chloral hydrate. E268Q-ALDH2 exhibited about
50% lower rates of superoxide formation than the WT
enzyme.
Conclusion
Our results suggest that E268 is involved in the structural
organization of the NAD binding pocket but is not
required for GTN denitration. Mechanism-based superox-
ide formation by ALDH2 may essentially account for oxi-
from 4th International Conference of cGMP Generators, Effectors and Therapeutic Implications
Regensburg, Germany. 19–21 June 2009
Published: 11 August 2009
BMC Pharmacology 2009, 9(Suppl 1):P72 doi:10.1186/1471-2210-9-S1-P72
<supplement> <title> <p>4th International Conference of cGMP Generators, Effectors and Therapeutic Implications</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1471-2210-9-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2210-9-S1-info.pdf</url> </supplement>
This abstract is available from: http://www.biomedcentral.com/1471-2210/9/S1/P72
© 2009 Wenzl et al; licensee BioMed Central Ltd. Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Pharmacology 2009, 9(Suppl 1):P72 http://www.biomedcentral.com/1471-2210/9/S1/P72
Page 2 of 2
(page number not for citation purposes)
dative stress in GTN-exposed blood vessels contributing
to nitrate tolerance.
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